CoChat

The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss

Rowe, Rachel, Cowx, Margaret, Poole, Chris, McEwan, Phil, Morgan, Christopher, Walker, Mel · 2005 · Current Medical Research and Opinion

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: In addition to direct weight reduction, there may be other benefits of obesity treatment including improved insulin sensitivity. The purpose of this study was to characterise concomitant diabetes drug use and the related costs in patients with diabetes treated with orlistat (Xenical) in the first 6 months of treatment. METHODS: One hundred overweight patients with diabetes and a body mass index (BMI) > or = 28 kg/m2 were enrolled in a structured UK hospital-based weight management clinic and treated with orlistat plus behavioural interventions. Among other measures, weight, glucose control (HbA1c) and drug treatment were recorded. Subjects were followed-up for a maximum of 24 months at intervals of 1-3 months, with a maximum treatment period of 24 months. RESULTS: The majority of subjects (91%) had type 2 diabetes. They had a mean age of 55 years and 55% were women. For patients followed up at 6 months, their mean BMI at baseline was 39.5 kg/m2 with a mean HbA1c of 7.6%. The mean weight loss at 6 months was 7.1 kg (p < 0.001). Despite a significant average absolute HbA1c reduction of 0.62% (p < 0.001), the most notable gains were made by those with the highest baseline HbA1c values (a mean relative reduction of 20% for those above the 75th percentile). There were 50 patients treated with insulin at baseline and 47 at 6 months. Of those treated with insulin, the mean dose was 130 units at baseline and 90 units at 6 months (p < 0.001). Twenty patients (44.4%) initially treated with oral hypoglycaemic agents alone reduced their dose after 6 months (not significant). Despite marked improvement in insulin sensitivity (baseline mean, 1.24 units/kg; 6 month mean, 0.90 units/kg [p < 0.001]) there was no correlation with BMI change. The average cost of diabetes treatment at baseline was pound 1.16 per day and pound 0.83 at 6 months (p < 0.001). Age was the only independent predictor for insulin dose reduction. CONCLUSIONS: Orlistat appears to reduce the need for concomitant diabetes medication irrespective of weight loss, a reduction that is likely to represent a large cost offset for orlistat treatment.

Overview

Integrity signals

Registry

Crossref · 10.1185/030079905x74943

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 27 references

Research works printed but not linked: 3

  1. Guerciolini R, 1997, Int J Obes Relat Metab Disord, 21, S12
  2. Hollander PA, 1998, A 1-year randomized double-blind study. Diabetes Care, 21, 1288
  3. Miles JM, 1671, Diabetes Care, 2002, 25

Cited by

See all 28

Metadata

Authors
Rowe, R., Cowx, M., Poole, C., McEwan, P., Morgan, C., & Walker, M.
Affiliations
  • Wythenshawe Hospital (GB)
  • Cardiff University (GB)
  • Roche (United Kingdom) (GB)
Corresponding author
McEwan, Phil
Venue
Current Medical Research and Opinion
Published
2005-10-18
Volume
21
Issue
11
Pages
1885-1890
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2155052156
Cited by
28
References
27
Citations by year
2024: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 2 · 2012: 1
FWCI
1.70
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
orlistat, type 2 diabetes, glycemic control, HbA1c, weight loss, obesity, insulin dose reduction, insulin sensitivity, weight management clinic, behavioral interventions, overweight patients, drug interactions, cost-effectiveness, body mass index, oral antidiabetic drugs
MeSH terms
Orlistat, Adult, Aged, Aged, 80 and over, Blood Glucose, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Lactones, Male, Middle Aged, Obesity, Prospective Studies, Weight Loss, Body Mass Index, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. https://app.cochat.ai/papers/10.1185/030079905x74943
The paper
Rowe, R., Cowx, M., Poole, C., McEwan, P., Morgan, C., & Walker, M. (2005). The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Current Medical Research and Opinion. https://doi.org/10.1185/030079905x74943

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.